Amaran Biotech’s AB-801 Adjuvant Recognized for Bioprocessing Excellence in Taiwan
TAIPEI, Taiwan, March 13, 2025 — Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), received the “Bioprocessing Excellence in Taiwan” award at the Asia-Pacific Biopharma Excellence Awards 2025. The ceremony, hosted by IMAPAC, a well-known consulting firm, took place in Singapore on March 12.
The Asia-Pacific Biopharma Excellence Awards, established in 2017, acknowledge exceptional achievements in bioprocessing, logistics, supply chain management, antibody-drug conjugates (ADC), and clinical trials across Asia. The awards program aims to promote progress within the biopharmaceutical sector. Amaran Biotech’s high-purity AB-801 adjuvant, created with its advanced bioprocessing technology, won after a nomination, shortlisting, and public voting process.
An adjuvant is a crucial vaccine ingredient that strengthens the body’s immune response, improving vaccine effectiveness and reducing the required dosage. Amaran Biotech’s AB-801 has similar application capabilities to QS-21, a globally recognized adjuvant sourced from the soap bark tree (Quillaja saponaria) found in Chile, Bolivia, and Peru. Saponin-based adjuvants are used in vaccines like GSK’s Shingrix® for shingles and the Novavax COVID-19 vaccine.
Dr. Tessie Che, Chairperson and General Manager of Amaran Biotech, commented: “AB-801 is a GMP-grade QS-21 adjuvant, and we are among the few CDMOs globally with the capacity to manufacture it. This award acknowledges our team’s hard work and commitment. We will continue improving our technologies to provide superior bioprocessing solutions to our international clients.” AB-801 is currently supplied to a leading global pharmaceutical company and has been adopted by research institutions and universities in Europe, North America, China, and Japan, as well as vaccine research organizations and manufacturers in China and India. Amaran Biotech intends to increase its production capacity to ensure a reliable supply for more international clients and to support the advancement of the global biotech industry.
About Amaran Biotech
Amaran Biotech is a CDMO specializing in drug process development, analytical services, and cGMP manufacturing of high-value biopharmaceuticals. Located in the Hsinchu Biomedical Science Park, Amaran Biotech’s advanced manufacturing facility has held PIC/S GMP certification from the TFDA since 2017. The company has also passed audits and received full qualification from regulatory agencies and third-party auditors in the USA and the EU. For more information, visit
Media Contact: Doreen Lin
“`
